U.S. plans shift of Merck’s COVID-19 treatment to commercial market

  • 📰 globeandmail
  • ⏱ Reading Time:
  • 33 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 16%
  • Publisher: 92%

Business News News

Business Business Latest News,Business Business Headlines

Merck said it needs an updated letter of authorization from the U.S. Food and Drug Administration to allow it to start selling the drug commercially

The U.S. government will stop distributing free doses of Merck & Co’s COVID-19 antiviral treatment molnupiravir by the middle of next month and expects it to be sold on the commercial market instead.

Merck, which developed the drug with Ridgeback Biotherapeutics, said in an e-mailed statement on Wednesday that it needs an updated letter of authorization from the U.S. Food and Drug Administration to allow it to start selling the drug commercially. It has taken a back seat to Paxlovid in the United States and the EU regulator recommended against the Merck drug’s use in the region.

It has also been linked to potentially transmissible mutations in the COVID-19 virus, according to a study published in the journal Nature last month. Merck said the study was limited and that it is confident in the clinical profile of the drug.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 5. in BUSİNESS

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

US plans shift of Merck COVID treatment to commercial marketBy Michael Erman (Reuters) - The U.S. government will stop distributing free doses of Merck & Co's COVID-19 antiviral treatment molnupiravir by the ...
Source: SaltWire Network - 🏆 45. / 63 Read more »